The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
Open accessAbstract
Primary myelofibrosis (PMF) is a fatal neoplastic disease characterized by clonal myeloproliferation and progressive bone marrow (BM) fibrosis thought to be induced by mesenchymal stromal cells stimulated by overproduced growth factors. However, tissue fibrosis in other diseases is associated with monocyte-derived fibrocytes. Therefore, we sought to determine whether fibrocytes play a role in the induction of BM fibrosis in PMF. In this study, we show that BM from patients with PMF harbors an abundance of clonal, neoplastic collagen- and fibronectin-producing fibrocytes. Immunodeficient mice transplanted with myelofibrosis patients’ BM cells developed a lethal myelofibrosis-like phenotype. Treatment of the xenograft mice with the fibrocyte inhibitor serum amyloid P (SAP; pentraxin-2) significantly prolonged survival and slowed the development of BM fibrosis. Collectively, our data suggest that neoplastic fibrocytes contribute to the induction of BM fibrosis in PMF, and inhibiting fibrocyte differentiation with SAP may interfere with this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Self-citationSomatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites
Abe, R., Donnelly, S. C., Peng, T., Bucala, R., & Metz, C. N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7556 · Cited by 967 · cited 3×
“, 2011), fibrocytes, spindle-shaped fibroblast-like cells that differentiate from a subpopulation of CD14 monocytes (Bucala et al., 1994; Abe et al., 2001; Yang et al., 2002; Pilling et al., 2003; Reilkoff et al., 2011), are associated with the induction of fibrosis.”
BackgroundAn Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm
Bottazzi, B., Doni, A., Garlanda, C., & Mantovani, A. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101305 · Cited by 592
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P
Murray, L. A., Chen, Q., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Peng, X., Gulati, M., Homer, R. J., Russell, T., van Rooijen, N., et al. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.013 · Cited by 362 · cited 2×
“Because levels of SAP, an inhibitor of fibrocyte differentiation, are reduced in patients with fibrotic diseases likely because of increased consumption (Castaño et al., 2009; Murray et al., 2011), we measured SAP in plasma samples from 39 patients with PMF and nine healthy age-matched individuals.”
BackgroundMethodReduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230
Self-citationHuman Serum Amyloid P Component is a Single Uncomplexed Pentamer in Whole Serum
Hutchinson, W. L., Hohenester, E., & Pepys, M. B. (2000) · Molecular Medicine · doi:10.1007/bf03401789 · Cited by 66 · cited 2×
“Notably, the differentiation of monocytes into fibrocytes is inhibited by the pentraxin protein serum amyloid P (SAP) component (pentraxin-2), a 125-kD protein produced by the liver (Steel and Whitehead, 1994; Hutchinson et al., 2000), repeated injections of which have been shown to ameliorate fibrosis in multiple org…”
Background
Cited by
Mack, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.11.010 · Cited by 514
Bone marrow niches in haematological malignancies
Méndez-Ferrer, S., Bonnet, D., Steensma, D. P., Hasserjian, R. P., Ghobrial, I. M., Gribben, J. G., Andreeff, M., & Krause, D. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0245-2 · Cited by 484
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
The Development of Serum Amyloid P as a Possible Therapeutic
Pilling, D., & Gomer, R. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02328 · Cited by 92
“Compared to controls, patients with renal fibrosis, pulmonary fibrosis, scleroderma, myelofibrosis, rheumatoid arthritis, and mixed connective tissue disease tend to have low levels of SAP, supporting the idea that fibrosis might in part involve a SAP deficiency (81, 98, 103, 117).”
BackgroundSelf-citationKramann, R., & Schneider, R. K. (2018) · Blood · doi:10.1182/blood-2018-02-834820 · Cited by 62
Metadata
- Authors
- Verstovsek, S., Manshouri, T., Pilling, D., Bueso-Ramos, C. E., Newberry, K. J., Prijic, S., Knez, L., Bozinovic, K., Harris, D. M., Spaeth, E. L., Post, S. M., Multani, A. S., Rampal, R. K., Ahn, J., Levine, R. L., Creighton, C. J., Kantarjian, H. M., & Estrov, Z.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-08-01
- Volume
- 213
- Issue
- 9
- Pages
- 1723-1740
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2493190817
- Cited by
- 161
- References
- 9
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.